Biomeditsina va amaliyot jurnali, 2022 №4
Subject of the article
MODERN VIEW ON ASCITE IN OVARIAN CANCER (130-139)
Authors
АБДУРАХМОНОВ Журабек Амриллоевич Республиканский специализированный научно-практический медицинский центр онкологии и радиологии, Самаркандский филиал РАХИМОВ Нодир Махамматкулович DSC ШАХАНОВА Шахноза Шавкатовна PhD Самаркандский Государственный медицинский университет
Institution
Самарқанд Давлат тиббиёт университети
Abstract
Хавфли асцит тухумдонлар саратонида тез тез учраб, шундан 10% гача бўлган холатларда беморлар тухумдонлар саратони рецидив билан азият чекадилар. Асцитик холат хар учтадан битта беморда тухумдон саратони ташхиси куйилган вактда ва рецидивланган беморларни деярли барчасида аникланади. Асцитнинг мавжудлиги тухумдонлар саратонини перитонеал йўл билан таркалишига туртки булади ва касаллик прогнозининг ёмонлашуви ушбу холат билан боглик. Хавфли асцит хужайра компонентлари ва эрувчан факторлар учун мураккаб аралашма сифатида таъсир этиб, усма хужайралари учун стимулловчи микроиклимни таъминлаб беради. Беморлар улими асосан усманинг корин бушлигида диссеменацияси ва метастазланиши билан боглик. Асцитик суюкликдан усма хужайралари олиниши асосий касаллик манбаи ва тухумдонлар саратонидан улимга олиб келишидан дарак беради. Ушбу усма хужайралари субпопуляцияси химиотерапияга юкори чидамли булиб, дистал метастазланиш ва рецидивланиш хусусиятига эгадир. Антиангиоген таргет препаратлари булиб хисобланган бевацизумаб ва пазопаниб хавфли асцитик суюклик билан кечувчи тухумдонлар саратонини симптоматик даволашда келгуси парацентезгача булган даврда узининг яхши эффектини курсатади. Шундай килиб, келгусида ушбу таргет препаратлар усма билан боглик асцитни камайтириши, беморнинг яшовчанлигини узайтиришини аниклаштиришмаксадида кенг куламли текширишлар утказиш зарур деген хулосага келдик. Калит сўз: тухумдонлар саратони, асцит, таргет терапия, бевизумаб, пазопаниб
Key words
Калит сўз: тухумдонлар саратони, асцит, таргет терапия, бевизумаб, пазопаниб
Literature
1. Ahmed N, Thompson EW, Quinn MA Epithelial-mesenchymal interconversions in normal ovarian surface epithelium and ovarian carcinomas: an exception to the norm. J Cell Physiol 213(3): 581-588, 2017. 2. Ahmed N, Stenvers KL : Getting to Know Ovarian Cancer Ascites: Opportunities for Targeted Therapy-Based Translational Research. Front Oncol 25;3: 256, 2013 3. Arni S, Cabiddu M, Ghilardi Muersperg N, Wong AS, Choi KC, Kang SK, Leung PC Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 22(2): 255-288, 2011) 4. Adam RA, Adam YG. Malignant ascites: past, present, and future. J Am Coll Surg (2014) 198(6):999–101110.1016/j.jamcollsurg.2014.01.03517 ). 5. Bansal S, Kaur K, Bansal AK: Diagnosing ascitic etiology on a biochemical basis. Hepatogastroenterology 45(23): 1673-1677, 2008 6. Bonnefoi H, A'Hern RP, Fisher C, Macfarlane V, Natural history of stage IV epithelial ovarian cancer. J Clin Oncol 17(3): 767-775, 2009 7. Burger RA Overview of anti-angiogenic agents in development for ovarian cancer. Gynecol Oncol 121(1): 230-238, 2011 8. Byrne AT, Ross L, Holash J, Nakanishi M, Hu L, Hofmann JI, et al. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res (2013) 9(15):5721–8 ). 9. Davidson B, Espina V, Steinberg SM, Florenes VA, Proteomic analysis of malignant ovarian cancer effusions as a tool for biologic and prognostic profiling. Clin Cancer Res 12(3 Pt 1): 791- 799, 2016). 10. Eskander RN, Tewari KS Emerging treatment options for management of malignant ascites in patients with ovarian cancer. Int J Womens Health 4: 395-404, 2012 11. Easson AM, Bezjak A, Ross S, The ability of existing questionnaires to measure symptom change after paracentesis for symptomatic ascites. Ann Surg Oncol 14(8): 2348-2357, 2017. 12. Eskander RN, Randall LM Bevacizumab in the treatment of ovarian cancer 13. El-Shami K, El-Kerm Y Open-label safety and efficacy pilot trial of intraperitoneal bevacizumab as palliative treatment in refractory malignant ascites. J Clin Oncol 25(No. 18S(20 Suppl)): 9043, 2017). 14. Fang X, Yu S, Bast RC, Aggarwal BB, Lu Y, Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells. J Biol Chem 279(10): 9653-9661, 2014 ). 15. Feldman GB, Knapp RC. Lymphatic drainage of the peritoneal cavity and its significance in ovarian cancer. Am J Obstet Gynecol (1974) 119(7):991–4 16. Ferrara N VEGF as a therapeutic target in cancer. Oncology 69(Suppl 3): 11-16, 2005 17. Friedlander M, Hancock KC, Rischin D, et al. A phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol. 2010;119:32–37du Bois A, Floquet A, 18. Gynecol Oncol (2012) 127(1):210–610.1016/j.ygyno.2012.05.002 19. Herr D, Sallmann A, Bekes I, Konrad R, Holzheu I, Kreienberg R, et al. VEGF induces ascites in ovarian cancer patients via increasing peritoneal permeability by downregulation of Claudin 20. Hamilton CA, Maxwell GL, Chernofsky MR, Bernstein SA, Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer. Gynecol Oncol 111(3): 530- 532, 2008 . 21. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ: Cancer statistics, CA Cancer J. Clin 55(1): 10-30, 2015 ). 22. Jemal A, Siegel R, Ward E, Hao Y, : Cancer statistics 2009. CA Cancer J Clin 59(4): 225- 249, 2009 23. Kobold S, Hegewisch-Becker S, Oechsle K, Jordan K, Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites? Oncologist 14(12): 1242-1251, 2017 . 24. Kassim SK, El-Salahy EM, Fayed ST, Helal SA, Helal T, Azzam Eel D, et al. Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients. Clin Biochem (2004) 37(5):363–910.1016/j.clinbiochem.2004.01.014 . 25. Kim JW, et al. Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol. 2014;32:3374–3382 ]. 26. Latifi A, Luwor RB, Bilandzic M, Nazaretian S, Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors. PLoS One 7(10): e46858, 2012 . 27. Monk BJ, Han E, Josephs-Cowan CA, Pugmire G, Burger RA Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer. Gynecol Oncol 102(2): 140-144, 2006 . 28. National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Ovarian cancer: including fallopian tube cancer and primary peritoneal cancer 2013;. Accessed 10/25, 2013 ). 29. Nuzhat Ahmed, Kaye L. Stenvers Getting to Know Ovarian Cancer Ascites: Opportunities for Targeted Therapy-Based Translational Research Front Oncol. 2013; 3: 256. Published online 2013 Sep doi: 10.3389/fonc.2013.00256 30. Numnum TM, Rocconi RP, Whitworth J, Barnes MN : The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma. Gynecol Oncol 102(3): 425- 428, 2016 31. Ozols RF, Bundy BN, Greer BE, Fowler JM, Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21(17): 3194-200, 2003 32. Petrelli F A novel perspective for an orphan problem: old and new drugs for the medical management of malignant ascites. Crit Rev Oncol Hematol 79(2): 144-153, 2011 33. Perez RP, Godwin AK, Hamilton TC, Ozols RF Ovarian cancer biology. 34. Rizvi I, Gurkan UA, Tasoglu S, Alagic N, Celli JP, Mensah LB, et al. Flow induces epithelialmesenchymal transition, cellular heterogeneity and biomarker modulation in 3D ovarian cancer nodules. Proc Natl Acad Sci U S A (2013) 110(22):E1974–8310.1073/pnas.1216989110 35. Shen-Gunther J, Mannel RS Ascites as a predictor of ovarian malignancy. Gynecol Oncol 87(1): 77-83, 2002 36. Stirling D, Evans DG, Pichert G, Shenton A, Kirk EN, Rimmer S, Steel CM, Lawson S, Screening for familial ovarian cancer: failure of current protocols to detect ovarian cancer at an early stage according to the international Federation of gynecology and obstetrics system. J Clin Oncol 23(24): 5588-5596, 2005 ). 37. Shield K, Ackland ML, Ahmed N, Rice GE Multicellular spheroids in ovarian cancer metastases: Biology and pathology. Gynecol Oncol 113(1): 143-148, 2009 38. Simpson-Abelson MR, Loyall JL, Lehman HK, Human ovarian tumor ascites fluids rapidly and reversibly inhibit T cell receptor-induced NF-kappaB and NFAT signaling in tumor-associated T cells. Cancer Immun 13: 14, 2013 39. Solle E,Ttaucher V Malignant Ascites in Ovarian Cancer and the Role of Targeted Therapeutics Anticancer Research April 2014 vol. 34 no. 4 1553-1561 40. Santin AD, Hermonat PL, Ravaggi A, Cannon MJ, Pecorelli S, Parham GP. Secretion of vascular endothelial growth factor in ovarian cancer. Eur J Gynaecol Oncol (2009) 20(3):177–8153. 41. Stoelcker B, Echtenacher B, Weich HA, Sztajer H, VEGF/Flk-1 interaction, a requirement for malignant ascites recurrence. J Interferon Cytokine Res 20(5): 511-517, 2015 ). 42. Tan DS, Agarwal R, Kaye SB. Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet Oncol (2006) 7(11):925–3410.1016/S1470-2045(06)70939-1 43. Urges A, Wimberger P, Kumper C, Gorbounova V, Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study. Clin Cancer Res 13(13): 3899-3905, 2016 44. Zebrowski BK, Liu W, Ramirez K, Markedly elevated levels of vascular endothelial growt